Clinical Trial for Fibrin Sealant in Knee Surgery
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00440921|
Recruitment Status : Withdrawn (No agreement between investigator and sponsor)
First Posted : February 27, 2007
Last Update Posted : June 2, 2015
- Thermogenesis is a company that sells a machine for the production of fibrin sealant of single donor plasma, the CryoSeal Fibrin Sealant System (CS-1).
- Fibrin sealant consists of two components: cryoprecipitate and thrombin. Cryoprecipitate is the fraction of human plasma that contains concentrated coagulation factors, such as fibrinogen. Thrombin is an enzyme that facilitates the conversion of fibrinogen into fibrin, so that a clot will be formed.
- Fibrin sealant can be used in surgery to increase hemostasis in the wound after e.g. knee- or hip replacement, cosmetical surgery or partial liverresections.
- Until now, mainly autologous plasma was used to produce fibrin sealant with the CS-1. Within Sanquin there is a question whether fibrin sealant can be produced from the allogeneic quarantaine plasma that is in stock. Therefore in this study will be studied whether allogenous single donor fibrin sealant produced using the CS-1 is effective in wound healing and as consequence of this can be registered as a product of Sanquin. To answer these questions a national working party is formed, working party Fibrin Sealant.
- So far, three man personnel in Sanquin Blood Bank Nort East Region (SBNO) are certified by Thermogenesis to use the CS-1 for production of fibrin sealant and an in vitro validation has been performed.
- The next step will be a study for the in vivo effectiveness of fibrin sealant produced of single donor allogeneic quarantaine plasma using the CS-1. As control patients without fibrin sealant treatment will be studied. Two hospitals (Refaja Hospital in Stadskanaal and Wilhelmina hospital in Assen) are already interested in participating in this study. Probably, three more hospitals will participate.
- The use of fibrin sealant will be studied in a prospective randomized trial for patients undergoing knee and hip replacements.
|Condition or disease||Intervention/treatment||Phase|
|Total Knee-replacement Total Hip-replacement||Drug: Single donor Allogenous Fibrin Sealant||Not Applicable|
Show Detailed Description
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||0 participants|
|Intervention Model:||Parallel Assignment|
|Primary Purpose:||Supportive Care|
|Official Title:||Randomized Clinical Trial for Fibrin Sealant in Knee Surgery|
|Study Start Date :||December 2008|
|Estimated Primary Completion Date :||December 2009|
|Estimated Study Completion Date :||June 2010|
- wound healing
- total blood loss until 24h post-operative
- amount of blood transfused
- motion of the joint (knee) after surgery
- amount of pain after surgery
- use of antibiotics
- wound infections
- stay in hospital
- adverse events
- satisfaction with fibrin sealant as used by the physician
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00440921
|Study Chair:||Coen van Delden, PhD||Sanquin Blood Bank North East Region|